Literature DB >> 15971061

A prospective study of lipoprotein(a) and risk of coronary heart disease among women with type 2 diabetes.

I Shai1, M B Schulze, J E Manson, M J Stampfer, N Rifai, F B Hu.   

Abstract

AIMS: We examined the association between lipoprotein (Lp)(a) and CHD among women with type 2 diabetes.
METHODS: Of 32,826 women from the Nurses' Health Study who provided blood at baseline, we followed 921 who had a confirmed diagnosis of type 2 diabetes.
RESULTS: During 10 years of follow-up (6,835 person-years), we documented 122 incident cases of CHD. After adjustment for age, smoking, BMI, glycosylated HbA(1)c, triglycerides (TGs), high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and other cardiovascular risk factors, the relative risk (RR) comparing extreme quintiles of Lp(a) was 1.95 (95% CI 1.07-3.56). The association was not appreciably altered after further adjustment for apolipoprotein B(100) or several inflammatory biomarkers. Increasing levels of Lp(a) were associated with lower levels of TGs. The probability of developing CHD over 10 years was higher among diabetic women with substantially higher levels of both Lp(a) (>1.07 micromol/l) and TGs (>2.26 mmol/l) than among diabetic women with lower levels (22 vs 10%, p log-rank test=0.049). Diabetic women with a higher level of only Lp(a) or TGs had a similar (14%) risk. In a multivariate model, diabetic women with higher levels of Lp(a) and TGs had an RR of 2.46 (95% CI 1.21-5.01) for developing CHD, as compared with those with lower levels of both biomarkers (p for interaction=0.413). The RRs for women with a higher level of either Lp(a) (RR=1.22, 95% CI 0.77-1.92) or TGs (RR=1.39, 95% CI 0.78-2.42) were comparable. CONCLUSIONS/
INTERPRETATION: Increased levels of Lp(a) were independently associated with risk of CHD among diabetic women.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15971061     DOI: 10.1007/s00125-005-1814-3

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  34 in total

1.  Correlation of apolipoprotein(a) isoproteins with Lp(a) density and distribution in fasting plasma.

Authors:  T Reblin; D J Rader; U Beisiegel; H Greten; H B Brewer
Journal:  Atherosclerosis       Date:  1992-06       Impact factor: 5.162

2.  Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a).

Authors:  S M Marcovina; J J Albers; A M Scanu; H Kennedy; F Giaculli; K Berg; R Couderc; F Dati; N Rifai; I Sakurabayashi; J R Tate; A Steinmetz
Journal:  Clin Chem       Date:  2000-12       Impact factor: 8.327

Review 3.  Kringle-dependent structural and functional polymorphism of apolipoprotein (a).

Authors:  A M Scanu; C Edelstein
Journal:  Biochim Biophys Acta       Date:  1995-04-28

4.  Differential influence of LDL cholesterol and triglycerides on lipoprotein(a) concentrations in diabetic patients.

Authors:  C Hernández; P Chacón; L García-Pascual; R Simó
Journal:  Diabetes Care       Date:  2001-02       Impact factor: 19.112

5.  Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid.

Authors:  L A Carlson; A Hamsten; A Asplund
Journal:  J Intern Med       Date:  1989-10       Impact factor: 8.989

6.  Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk.

Authors:  Sophie Gonbert; Sophie Malinsky; Andrei C Sposito; Hervé Laouenan; Chantal Doucet; M John Chapman; Joëlle Thillet
Journal:  Atherosclerosis       Date:  2002-10       Impact factor: 5.162

7.  Prospective study of lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients with diabetes.

Authors:  T Hiraga; T Kobayashi; M Okubo; K Nakanishi; T Sugimoto; Y Ohashi; T Murase
Journal:  Diabetes Care       Date:  1995-02       Impact factor: 19.112

8.  Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients.

Authors:  M Rath; A Niendorf; T Reblin; M Dietel; H J Krebber; U Beisiegel
Journal:  Arteriosclerosis       Date:  1989 Sep-Oct

9.  Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group.

Authors: 
Journal:  Diabetes       Date:  1979-12       Impact factor: 9.461

10.  Inflammatory markers and risk of developing type 2 diabetes in women.

Authors:  Frank B Hu; James B Meigs; Tricia Y Li; Nader Rifai; JoAnn E Manson
Journal:  Diabetes       Date:  2004-03       Impact factor: 9.461

View more
  11 in total

Review 1.  Cardiovascular risk assessment in type 2 diabetes mellitus.

Authors:  Ebaa Al-Ozairi; R Jan-Willem Middelbeek; Edward S Horton
Journal:  Curr Diab Rep       Date:  2006-11       Impact factor: 4.810

2.  A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease.

Authors:  G Tuncman; E Erbay; X Hom; I De Vivo; H Campos; E B Rimm; G S Hotamisligil
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-25       Impact factor: 11.205

3.  Circulating leptin levels are not associated with cardiovascular morbidity and mortality in women with diabetes: a prospective cohort study.

Authors:  A M Brennan; T Y Li; I Kelesidis; A Gavrila; F B Hu; C S Mantzoros
Journal:  Diabetologia       Date:  2007-03-20       Impact factor: 10.122

4.  Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes.

Authors:  Qibin Qi; Tsegaselassie Workalemahu; Cuilin Zhang; Frank B Hu; Lu Qi
Journal:  Eur Heart J       Date:  2011-09-06       Impact factor: 29.983

5.  Levels of Apolipoprotein A1, B100 and Lipoprotein (a) in Controlled and Uncontrolled Diabetic Patients and in Non-Diabetic Healthy People.

Authors:  Vishwal Indravadan Patel; Kinjal Prahaladbhai Patel; Mayur Goradhanbhai Makadia; Aashna Darshanbhai Shah; Kaushik Salubhai Chaudhari; Haridas Neelakandan Nilayangode
Journal:  J Clin Diagn Res       Date:  2017-02-01

6.  Lipoprotein(a) is strongly associated with coronary artery calcification in type-2 diabetic women.

Authors:  Atif N Qasim; Seth S Martin; Nehal N Mehta; Megan L Wolfe; James Park; Stanley Schwartz; Mark Schutta; Nayyar Iqbal; Muredach P Reilly
Journal:  Int J Cardiol       Date:  2010-03-19       Impact factor: 4.164

7.  Lipoprotein(a) and cardiovascular disease in diabetic patients.

Authors:  Qibin Qi; Lu Qi
Journal:  Clin Lipidol       Date:  2012-08

8.  Lipoprotein(a): an independent risk factor for ischemic heart disease that is dependent on triglycerides in subjects with type 2 diabetes mellitus.

Authors:  Ali Albahrani; Mohammed Alkindi; Eileen Marks; Said Alyahyaee; Alan Shenkin
Journal:  Lipids Health Dis       Date:  2007-10-02       Impact factor: 3.876

Review 9.  The relationship between Lp(a) and CVD outcomes: a systematic review.

Authors:  Carol A Forbes; Ruben G W Quek; Sohan Deshpande; Gill Worthy; Robert Wolff; Lisa Stirk; Jos Kleijnen; Shravanthi R Gandra; Stephen Djedjos; Nathan D Wong
Journal:  Lipids Health Dis       Date:  2016-05-17       Impact factor: 3.876

10.  Elevated lipoprotein(a) levels predict cardiovascular disease in type 2 diabetes mellitus: a 10-year prospective cohort study.

Authors:  Tae-Seok Lim; Jae-Seung Yun; Seon-Ah Cha; Ki-Ho Song; Ki-Dong Yoo; Yu-Bae Ahn; Yong-Moon Park; Seung-Hyun Ko
Journal:  Korean J Intern Med       Date:  2016-10-18       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.